Changes in the pulmonary function of CT‑guided microwave ablation for patients with malignant lung tumors.

Purpose: To investigate the changes in pulmonary function after computed tomography (CT)‑guided microwave ablation (MWA) in patients with a malignant lung tumor. Materials and Methods: From June 2020 to January 2022, 133 patients with a malignant lung tumor who underwent CT‑guided percutaneous MWA were included in the study. Pulmonary function tests (PFTs) were performed before (the baseline) and 1 month after the MWA. Vital capacity (VC), forced vital capacity (FVC), forced expiratory volume in 1 second (FEV1), FEV1%, maximum mid‑expiratory flow (MMEF), and diffusion capacity of the lung for carbon monoxide (DLCO‑SB) at 1 month post MWA were compared with that at the baseline. The time of procedure and post‑procedure length of hospital stay were also recorded. Results: The mean VC, FVC, FEV1, FEV1%, MMEF, and DLCO‑SB at the baseline and 1 month post MWA were 3.23 ± 0.75 and 3.22 ± 0.77 (P = 0.926), 3.20 ± 0.75 and 3.21 ± 0.77 (P = 0.702), 2.35 ± 0.70 and 2.35 ± 0.71 (P = 0.992), 91.97 ± 23.14 and 91.87 ± 23.16 (P = 0.837), 1.83 ± 0.93 and 1.81 ± 0.95 (P = 0.476), and 6.38 ± 1.67 and 6.32 ± 1.62 (P = 0.389), respectively. There was no significant difference in the PFT results before and 1 month post MWA. The mean time of procedure and post‑MWA length of hospital stay were 33 min and 2.5 days, respectively. Conclusions: MWA is a lung parenchyma‑sparing local treatment, and pulmonary function at 1 month post MWA was not statistically different from the baseline, indicating that MWA may not affect pulmonary function. [ABSTRACT FROM AUTHOR]